These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 25320633)

  • 41. Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial.
    Diaz RS; Shytaj IL; Giron LB; Obermaier B; Della Libera E; Galinskas J; Dias D; Hunter J; Janini M; Gosuen G; Ferreira PA; Sucupira MC; Maricato J; Fackler O; Lusic M; Savarino A;
    Int J Antimicrob Agents; 2019 Nov; 54(5):592-600. PubMed ID: 31394172
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).
    Ndhlovu LC; Umaki T; Chew GM; Chow DC; Agsalda M; Kallianpur KJ; Paul R; Zhang G; Ho E; Hanks N; Nakamoto B; Shiramizu BT; Shikuma CM
    J Neurovirol; 2014 Dec; 20(6):571-82. PubMed ID: 25227930
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption.
    Ziani W; Shao J; Wang X; Russell-Lodrigue K; Liu YZ; Montaner LJ; Veazey RS; Xu H
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33408173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
    Shytaj IL; Norelli S; Chirullo B; Della Corte A; Collins M; Yalley-Ogunro J; Greenhouse J; Iraci N; Acosta EP; Barreca ML; Lewis MG; Savarino A
    PLoS Pathog; 2012; 8(6):e1002774. PubMed ID: 22737073
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment Intensification in HIV-Infected Patients Is Associated With Reduced Frequencies of Regulatory T Cells.
    Grützner EM; Hoffmann T; Wolf E; Gersbacher E; Neizert A; Stirner R; Pauli R; Ulmer A; Brust J; Bogner JR; Jaeger H; Draenert R
    Front Immunol; 2018; 9():811. PubMed ID: 29760693
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.
    Bonjoch A; Pou C; Pérez-Álvarez N; Bellido R; Casadellà M; Puig J; Noguera-Julian M; Clotet B; Negredo E; Paredes R
    J Antimicrob Chemother; 2013 Jun; 68(6):1382-7. PubMed ID: 23354282
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.
    Byakwaga H; Kelly M; Purcell DF; French MA; Amin J; Lewin SR; Haskelberg H; Kelleher AD; Garsia R; Boyd MA; Cooper DA; Emery S;
    J Infect Dis; 2011 Nov; 204(10):1532-40. PubMed ID: 21930607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modelling HIV-1 2-LTR dynamics following raltegravir intensification.
    Luo R; Cardozo EF; Piovoso MJ; Wu H; Buzon MJ; Martinez-Picado J; Zurakowski R
    J R Soc Interface; 2013 Jul; 10(84):20130186. PubMed ID: 23658114
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals.
    Morón-López S; Navarro J; Jimenez M; Rutsaert S; Urrea V; Puertas MC; Torrella A; De Clercq L; Ribas BP; Gálvez C; Salgado M; Vandekerckhove L; Blanco J; Crespo M; Martinez-Picado J
    Clin Infect Dis; 2019 Sep; 69(8):1320-1328. PubMed ID: 30590412
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
    Katlama C; Assoumou L; Valantin MA; Soulié C; Duvivier C; Chablais L; Kolta S; Pialoux G; Mercié P; Simon A; Costagliola D; Peytavin G; Marcelin AG;
    J Antimicrob Chemother; 2014 Jun; 69(6):1648-52. PubMed ID: 24535278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study.
    Krikke M; Tesselaar K; Arends JE; Drylewicz J; Otto SA; van Lelyveld SF; Visseren FJ; Hoepelman AI
    Infect Dis Ther; 2016 Sep; 5(3):389-404. PubMed ID: 27300170
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
    Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.
    Cuzin L; Trabelsi S; Delobel P; Barbuat C; Reynes J; Allavena C; Peytavin G; Ghosn J; Lascoux-Combe C; Psomas C; Corbeau P; Flandre P;
    J Acquir Immune Defic Syndr; 2012 Dec; 61(5):557-64. PubMed ID: 22986949
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Suppression of Active HIV-1 Infection in CD34
    Latinovic OS; Neal LM; Tagaya Y; Heredia A; Medina-Moreno S; Zapata JC; Reitz M; Bryant J; Redfield RR
    AIDS Res Hum Retroviruses; 2019 Aug; 35(8):718-728. PubMed ID: 31099257
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
    Charpentier C; Fagard C; Colin C; Katlama C; Molina JM; Jacomet C; Visseaux B; Taburet AM; Brun-Vézinet F; Chêne G; Yazdanpanah Y; Descamps D;
    PLoS One; 2013; 8(1):e53621. PubMed ID: 23349724
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single-molecule techniques to quantify and genetically characterise persistent HIV.
    Wang XQ; Palmer S
    Retrovirology; 2018 Jan; 15(1):3. PubMed ID: 29316955
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.
    Dahl V; Lee E; Peterson J; Spudich SS; Leppla I; Sinclair E; Fuchs D; Palmer S; Price RW
    J Infect Dis; 2011 Dec; 204(12):1936-45. PubMed ID: 22021620
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
    Yilmaz A; Verhofstede C; D'Avolio A; Watson V; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):590-6. PubMed ID: 20847699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.
    Omondi FH; Chandrarathna S; Mujib S; Brumme CJ; Jin SW; Sudderuddin H; Miller RL; Rahimi A; Laeyendecker O; Bonner P; Yue FY; Benko E; Kovacs CM; Brockman MA; Ostrowski M; Brumme ZL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30602611
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HIV-Specific Granzyme B-Secreting but Not Gamma Interferon-Secreting T Cells Are Associated with Reduced Viral Reservoirs in Early HIV Infection.
    Yue FY; Cohen JC; Ho M; Rahman AKMN; Liu J; Mujib S; Saiyed A; Hundal S; Khozin A; Bonner P; Liu D; Benko E; Kovacs C; Ostrowski M
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.